Currently, there are 30.81M common shares owned by the public and among those 26.83M shares have been available to trade.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 77,673 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 3,800 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 1.84% and 66.93% over the past three months. URGN shares are trading 28.87% year to date (YTD), with the 12-month market performance up to 110.80% higher. It has a 12-month low price of $7.75 and touched a high of $24.13 over the same period. URGN has an average intraday trading volume of 315.10K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 16.12%, 25.37%, and 37.41% respectively.
Institutional ownership of UroGen Pharma Ltd (NASDAQ: URGN) shares accounts for 72.90% of the company’s 30.81M shares outstanding.
It has a market capitalization of $595.56M and a beta (3y monthly) value of 1.09. The earnings-per-share (ttm) stands at -$4.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.03% over the week and 5.65% over the month.
Analysts forecast that UroGen Pharma Ltd (URGN) will achieve an EPS of -$0.68 for the current quarter, -$0.73 for the next quarter and -$2.63 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.74 while analysts give the company a high EPS estimate of -$0.61. Comparatively, EPS for the current quarter was -$1.22 a year ago. Earnings per share for the fiscal year are expected to increase by 25.59%, and 26.32% over the next financial year.
Looking at the support for the URGN, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on February 08, 2023, with the firm’s price target at $35-$10.
